<DOC>
	<DOCNO>NCT00553618</DOCNO>
	<brief_summary>The purpose study see combination two cancer drug , Dacarbazine ( DTIC ) low-dose Proleukin ( IL2 ) , would provide less toxic effective treatment melanoma currently available treatment people high-risk melanoma . Dacarbazine ( DTIC ) Proleukin ( IL2 ) FDA-approved drug treatment melanoma .</brief_summary>
	<brief_title>Adjuvant , Combined Interleukin 2 ( Proleukin ) DTIC ( Dacarbazine ) High-risk Melanoma Patients</brief_title>
	<detailed_description>The prognosis patient malignant melanoma great 4 mm deep involve regional lymph node poor , even successful surgical removal . The concept adjuvant therapy melanoma derive hypothesis therapy may kill micro-metastatic seed melanoma cell . The rationale particular drug combination regimen melanoma cell may act vaccine generate melanoma-specific T cell expansion way IL2 administration . In unpublished result , forty-two stage II III melanoma patient treat regimen University Alabama IRB approval . Analysis relapse free survival overall survival patient treat combination suggest small improvement disease-free survival compare historical control another study whose patient similar identical staging ( median follow-up time 30 month ) . Importantly , unanticipated side effect observe result combination two drug ( FDA-approved use melanoma patient ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patients must fulfill one follow criterion : T4 NO MO Deep primary melanoma ( &gt; 4.0 mm ) without lymphadenectomy . T14 N13 MO Primary melanoma regional lymph node metastases find lymphadenectomy sentinel lymph node sampling , clinically undetectable ( occult ) . T14 N13 MO Primary melanoma clinically apparent ( overt ) regional lymph node metastasis confirm lymphadenectomy . T14 N13 MO Recurrence melanoma proximal regional lymph node ( ) . Patients must undergo wide excision primary , &gt; 1mm depth , complete sentinel lymph node sample lymphadenectomy standard practice . Patients must confirmation adequate surgical margin around primary lesion ( 1 2 cm minimum , primary lesion 12 mm depth ; 2 cm primary lesion equal great 2 mm depth ) . When enter study recurrent regional lymph node disease , patient must enrol later 90 day date lymphadenectomy . For subungual melanoma distal interphalangeal . amputation require . For patient regional lymph node recurrence , evidence adequate margin around primary required patient initial presentation . For safety reason , patient must age 18 85 . Patients must ECOG performance status 02 . Patients must WBC &gt; 3,000 , platelet count &gt; 100,000 , hematocrit &gt; 33 . Patients must SGOT bilirubin &lt; 2x normal ; creatinine &lt; 2.3 ; BUN &lt; 33 . Patients must active medical psychiatric disorder require therapy would prevent completion protocol . Patients must give write informed consent . Patients histopathologic examination primary metastatic melanoma positive ineligible . Patients clinical , radiological , laboratory , pathological evidence incompletely resect melanoma distant metastatic disease ineligible . Patients active second cancer ( except situ cervical cancer , basal squamous skin cancer ) ineligible . Exceptions may discuss principal investigator . Patients organic brain syndrome significant impairment basal cognitive function psychiatric disorder might preclude participation full protocol , ineligible . Patients prior adjuvant chemotherapy , immunotherapy , include preoperative infusion perfusion therapy ineligible . Patients recurrent melanoma regional lymph node must previously enter study . Patients one lymph node group involve ineligible . Women child bear age adequate birth control ineligible . Women pregnant breast feeding ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Interleukin 2</keyword>
	<keyword>Proleukin</keyword>
	<keyword>DTIC</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>metastatic melanoma</keyword>
	<keyword>adjuvant</keyword>
</DOC>